Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
acf-ui-options-page
omapi
acf-taxonomy
acf-post-type
pha_member
lgx_lsp_shortcodes
speaker
e-book

First Allogeneic Stem Cell Transplant Therapy Approved by the FDA

Banner
Anna Osborne
19 April 2023
SHARE NOW
Allogeneic
Cell Therapy
Clinical Trials
GMP
Stem Cells
Cell therapy pioneer Gamida Cell has announced the FDA has approved its allogeneic cell therapy Omisirge, as a source of stem cell transplant for patients with hematological malignancies.

As the first allogenic stem cell transplant therapy to be approved, Omisirge takes cells from a donor and will be used to treat adults and pediatric patients over 12 years old with hematological malignancies including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid malignancies, and myelodysplastic syndromes, planned for umbilical cord blood transfusions following myeloablative conditioning.

Manufactured in Gamida’s state-of-the-art GMP manufacturing facility in Israel, Omisirge works to enhance and expand the number of progenitor cells utilizing proprietary nicotinamide technology in order to preserve their stemness, homing to bone marrow and retained engraftment capacity and is delivered to patients in transplant centers within 30 days.

“FDA approval of Omisirge is a major advancement in the treatment of patients with hematologic malignancies that we believe may increase access to stem cell transplant and help improve patient outcomes,” said Abbey Jenkins, President and CEO of Gamida Cell.

How are you enjoying this news article? Let us know your thoughts, here >>

 

The FDA approval was based on the results of Gamida’s global, randomized Phase III clinical trial in which Omisirge demonstrated faster neutrophil recovery and reduced bacterial and fungal infection in the treated patients, compared with standard cord blood transplants.

Gamida shared in the official journal of the American Society of Hematology, that Omisirge had a median time to neutrophil recovery of 12 days – 10 days quicker than the 22 days of standard cord blood.

The safety profile reported from the Phase III trial was consistent with the expected adverse events of allogeneic hematopoietic stem cell transplants following myeloablative conditioning.

Patients can now access this treatment in U.S. transplant centers, with Omisirge set to help address health disparities in stem cell transplants.

 “Patients who are Black or African American have just a 29% chance of finding a match via the donor registry vs. a 79% chance for patients who are White.3 Adding Omisirge as a new donor source may help increase access to stem cell transplant for patients from racially or ethnically diverse backgrounds who struggle to find a fully matched donor in the registry,” said Steven M. Devine, M.D., Chief Medical Officer at the National Marrow Donor Program® (NMDP)/Be The Match®.

Following the recent collaboration with strategic advisor Moelis & Company, Gamida continues to pursue strategic partnerships in order to support the launch and commercialization of Omisirge across the U.S and the rest of the world.

Source: Gamida Cell Press Release


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.

More like this

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.
4 December 2023

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Oxford Biomedica Acquires ABL Europe from Institut Mérieux
6 December 2023

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

Two female pediatric patients with Rett syndrome were the first children worldwide to receive the promising treatment with Neurogene’s lead gene therapy product.
5 December 2023

Discover more like this

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies

Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022